ISSN: 0973-7510

E-ISSN: 2581-690X

Review Article | Open Access

Gauravi N. Trivedi1, Janhavi T. Karlekar2, Hiren A. Dhameliya1 and Hetalkumar Panchal1

1Post Graduate Department of Biosciences, Sardar Patel University, Satellite Campus, Bakrol-Vadtal Road, Bakrol, Anand – 388 315, Gujarat, India.
2Indukaka Ipcowala Centre for Interdisciplinary Studies in Science and Technology, Sardar Patel University, Nr. Bus Stop, B/h Shastri Maidan, Vallabh Vidyanagar – 388 120, Gujarat, India.
J Pure Appl Microbiol. 2020;14(suppl 1):849-860 | Article Number: 6312
Received: 30/04/2020 | Accepted: 14/05/2020 | Published: 17/05/2020

Coronavirus Disease (COVID-19) is a new disease that emerged in Wuhan, China which spreads through close contact of people, often by small droplets produced during coughing or sneezing. Detail mechanism by which it spreads between people are under investigation. The World Health Organization (WHO) declared this disease as a pandemic after the severity of the disease increased. Many scientific reports gathered have suggested many drugs that could be potential candidates for the treatment. Although, clinical effectiveness has not been fully evaluated. In this review, we have aggregated the data from few research articles, official news websites and few review papers regarding its phylogenetic relation, genomic constitution, transmission, replication and in-silico analysis done by researchers for few potent drugs that are currently used to cure COVID-19. SARS-CoV-2 belongs to Betacoronavirus genus with Genome structure consists 14 Open Reading Frames (ORFs) that encode 27 proteins. Coronavirus replicates into the host cells having unique mechanisms like ribosome frame-shifting and synthesis of genomic and sub genomic RNAs. In-silico methods have the advantage that they can make fast predictions for a large set of compounds in a high-throughput mode and also make their prediction based on the structure of a compound even before it has been synthesized. In-silico softwares have been used to find or to improve a novel bioactive compound, which may exhibit a strong affinity to a particular target in the drug development process.


COVID-19, SARS-CoV-2, SARS-CoV, MERS-CoV, Pandemic, WHO

Article Metrics

Article View: 535

Share This Article

© The Author(s) 2020. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.